<DOC>
	<DOCNO>NCT01331850</DOCNO>
	<brief_summary>This randomize , open-label , multi-center study evaluate sustain virological response , pharmacokinetics safety various combination danoprevir/ritonavir Copegus plus RO5024048 and/or Pegasys patient chronic hepatitis C infection . Patients divide 2 separate cohort . Cohort A , previous partial responder , randomize Groups 1-3 cohort B , previous null responder , randomize Groups 4-6 . Patients group receive danoprevir 100 mg twice day ritonavir 100 mg twice day 24 week . In addition , Groups 1 4 receive RO5024048 1000 mg twice day Copegus 1000 mg 1200 mg twice day 24 week ; Group 2 receive Pegasys 180 microgram subcutaneously weekly Copegus 1000 mg 1200 mg twice day 24 week ; Groups 3 , 5 6 receive RO5024048 1000 mg twice day , Pegasys 180 microgram subcutaneously weekly Copegus 1000 mg 1200 mg twice day 24 week . In addition , patient Group 6 receive another 24 week Pegasys plus Copegus treatment .</brief_summary>
	<brief_title>A Study Danoprevir/Ritonavir Copegus With RO5024048 and/or Pegasys Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Adult patient , age 18 year old Presence hepatitis C infection , genotype 1a 1b Documentation previous treatment failure receive approve dos peginterferon plus ribavirin least 12 week Patients must discontinue prior hepatitis C treatment least 12 week prior study start Infection hepatitis C genotype subtype genotype 1a 1b Patients cirrhosis Patients discontinue previous peginterferon plus ribavirin therapy due reason insufficient therapeutic response Coinfection hepatitis B human immunodeficiency virus ( HIV ) History evidence chronic liver disease hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>